Market revenue in 2021 | USD 3.7 million |
Market revenue in 2030 | USD 7.2 million |
Growth rate | 7.7% (CAGR from 2021 to 2030) |
Largest segment | Biomarker assay development & validation |
Fastest growing segment | Flow cytometry |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biomarker Assay Development & Validation, Flow cytometry, Others( Biomarker immunoassays, Biomarker Assessment) |
Key market players worldwide | Eurofins Scientific SE, SGS AG, Charles River Laboratories International Inc, Labcorp Drug Development, Thermo Fisher Scientific Inc, Icon PLC, IQVIA Holdings Inc, Syneos Health, Intertek Group PLC, BioAgilytix Labs |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biomarker testing services market will help companies and investors design strategic landscapes.
Biomarker assay development & validation was the largest segment with a revenue share of 59.46% in 2024. Horizon Databook has segmented the Taiwan biomarker testing services market based on biomarker assay development & validation, flow cytometry, others( biomarker immunoassays, biomarker assessment) covering the revenue growth of each sub-segment from 2018 to 2030.
Taiwan has become a preferred destination for clinical trials due to its growing market for drug development, expanding population, and comprehensive healthcare system. The rising requirement for therapeutics in the country is expected to boost its requirement among pharmaceutical companies, further propelling the market.
For instance, in May 2024, Boditech Med mentioned signing a Memorandum of Understanding with Bio Preventive Medicine Corp., a company based in Taiwan, for a biomarker license for predicting diabetic kidney disease known as DNlite-IVD103.
Horizon Databook provides a detailed overview of country-level data and insights on the Taiwan biomarker testing services market , including forecasts for subscribers. This country databook contains high-level insights into Taiwan biomarker testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account